insights_auto
Sebab TRVN meningkat 450.00%?
Terokai Dengan Lebih Terperincichevron_right
TRVN:OTCMKTS
Trevena Inc
USD 0.066
arrow_upward
+450.00%(+0.054) 1H
12 Okt, 4:00:00 PTG GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk TRVN...
Buka
USD 0.07
Tinggi
USD 0.07
Rendah
USD 0.07
Permodalan Pasaran
68.44K
Purata volum
182.00
Volum
833.00
tgi 52 mgu
USD 1.50
rdh 52 mgu
USD 0.00
Beta
1.07
Syer tertunggak
864.00K
Bilangan pekerja
23
Buka
USD 0.07
Tinggi
USD 0.07
Rendah
USD 0.07
Permodalan Pasaran
68.44K
Purata volum
182.00
Volum
833.00
tgi 52 mgu
USD 1.50
rdh 52 mgu
USD 0.00
Beta
1.07
Syer tertunggak
864.00K
Bilangan pekerja
23
Cerita berita
Daripada sumber web dan rakan kongsi berita
Invezz
·
9 jam lalu
3 pemangkin utama untuk Indeks S&P 500 minggu ini: bon, musim laporan pendapatan, CPI
Invezz
·
8 jam lalu
Dow Jones dibuka 190 mata lebih tinggi, pelabur memerhati pendapatan bank dan inflasi
Invezz
·
1 jam lalu
Dow naik 198 mata, saham AS bercampur menjelang keputusan pendapatan
www.marketscreener.com
·
56 minit lalu
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Perihal Trevena Inc